Patents Examined by Sagar Patel
  • Patent number: 10100043
    Abstract: Provided are cycloalkyl- and cycloalkenyl-substituted benzaldehydes and heteroaldehydes of formula (I) that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions containing the modulators, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 16, 2018
    Assignees: Global Blood Therapeutics, Inc., Cytokinetics, Inc.
    Inventors: Brian Metcalf, Chihyuan Chuang, Zhe Li
  • Patent number: 10100060
    Abstract: This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: October 16, 2018
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Ronen Ben-David, Jian Chen, Michael A. Christie, Mina Gadelrab Dimitri, Graciela Noemi Gershon, Linli He, Nelson G. Landmesser, Daniel V. Levy, Orel Yosef Mizrahi, Partha S. Mudipalli, Harlan F. Reese, Joseph A. Sclafani, Yi Wang
  • Patent number: 10093621
    Abstract: The present invention relates to a compound having formula (I) below or a pharmaceutically acceptable salt thereof: wherein: X is —COOH or NH2; R is a straight or branched C1-C10 alkylene chain; and R1 is H, straight or branched C1-C10 alkyl, aryl, or R2CO— wherein R2 is straight or branched C1-C10 alkyl, for use as antitumoral agents.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 9, 2018
    Assignee: FONDAZIONE IRCCS INSTITUTO NAZIONALE DEI TUMORI
    Inventors: Maria Grazia Daidone, Valentina Appierto, Paola Tiberio, Sabrina Dallavalle, Loana Musso, Elisa Niccolini
  • Patent number: 10093628
    Abstract: The present invention pertains to a new compound E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trifluoromethyl) benzyl)oxy)-benzylidene) hexanoic acid (MTTB), and its derivatives. The compounds of the invention are useful as selective peroxisome proliferator-activated receptor gamma (PPAR?) antagonists and are indicated for the use in the treatment of immune related diseases such as systemic inflammation, sepsis and septic shock.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: October 9, 2018
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Tilo Knape, Andreas Von Knethen, Michael John Parnham, Manfred Schubert-Zsilavecz, Mario Wurglics, Daniel Flesch
  • Patent number: 10085969
    Abstract: Provided herein are compounds and formulations thereof that can be capable of binding to sortilin or an analog thereof. Also provided herein are methods of administering the compounds and formulation provided herein to a subject in need thereof.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: October 2, 2018
    Assignees: University of South Florida, University of Rochester
    Inventors: Robert Pleasants Sparks, Wayne Charles Guida, Janet Lindsay DeHoff-Sparks
  • Patent number: 10086085
    Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: October 2, 2018
    Assignee: Pfizer Inc.
    Inventors: Andreas Maderna, Matthew David Doroski, Zecheng Chen, Hud Lawrence Risley, Jeffrey Michael Casavant, Christopher John O'Donnell, Alexander M. Porte, Chakrapani Subramanyam
  • Patent number: 10081620
    Abstract: There is provided a labeling precursor compound represented by the following general formula (2): wherein R1 represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R2 and R3 each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R6 represents an alkyl group or —CONR11R12 wherein R11 and R12 each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R4, R5, R7 and R8 each independently represent a hydrogen atom, an alkyl group or an alkoxy group.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: September 25, 2018
    Assignees: NIHON MEDI-PHYSICS CO., LTD., TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Masahito Toyama, Masato Kiriu, Hiroshi Tanaka
  • Patent number: 10065926
    Abstract: The invention relates to the use of substituted dihydrooxindolylsulfonamides or salts thereof of the formula (I) where the radicals in the general formula (I) correspond to the definitions given in the description, for enhancing stress tolerance in plants to abiotic stress, and/or for increasing plant yield.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: September 4, 2018
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Jens Frackenpohl, Guido Bojack, Hendrik Helmke, Stefan Lehr, Thomas Mueller, Lothar Willms, Jan Dittgen, Dirk Schmutzler, Udo Bickers, Harry Strek, Rachel Baltz
  • Patent number: 10045963
    Abstract: Disclosed are methods for the preparation of amorphous N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus. Also disclosed are methods for the preparation of amorphous solid dispersion of N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: August 14, 2018
    Assignee: SIGA TECHNOLOGIES, INC.
    Inventors: Shanthakumar R. Tyavanagimatt, N K Peter Samuel, Joseph Paz, Ying Tan, Dennis E. Hruby
  • Patent number: 10035762
    Abstract: The present invention relates to the synthesis of succinimides, in particular to a method for the synthesis of a succinimide compound, comprising the step of reacting an alkyne, with carbon monoxide and ammonia or an amine, in the presence of an iron catalyst, wherein the reaction is carried out in an amine liquid phase and/or in the absence of an ether solvent. The succinimides may be reduced to quaternary ammonium cations which may be used as structure directing agents in the synthesis of molecular sieves.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 31, 2018
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Kirk D. Schmitt, Stephen Zushma, Allen W. Burton
  • Patent number: 10035760
    Abstract: Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth:
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: July 31, 2018
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Annapurna Pendri, Guo Li, John A. Bender, Zhong Yang, Alan Xiangdong Wang, Brett R. Beno, Robert A. Fridell, Makonen Belema, Nicholas A. Meanwell, Robert G. Gentles
  • Patent number: 10035774
    Abstract: Pyrazolyl carboxylic acid and pyrazolyl urea derivatives have been synthesized, which are useful in the manufacture of cephalosporin antibiotic compounds.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 31, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kristos Adrian Moshos, Valdas Jurkauskas, Yisheng Yang, Youchu Wang
  • Patent number: 10028935
    Abstract: Disclosed are novel stable compounds having anti-oxidant properties and methods of using the compounds for the treatment of diseases or injuries associated with oxidative stress.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: July 24, 2018
    Assignee: XPD Holdings, LLC
    Inventors: Marc Bailie, Steven K. Duddy, Jim Herman
  • Patent number: 10005740
    Abstract: In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: June 26, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Anne-Marie Beausoleil, Adam D. Hughes, Daniel D. Long, Donna A. A. Wilton
  • Patent number: 9993484
    Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: June 12, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Lars Wortmann, Ulrich Lücking, Julien LeFranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
  • Patent number: 9994524
    Abstract: The T cells specific to human collagen type II, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of HLA-DR4. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen linked to the allele MHC of class II HLA-DR4 may thus represent the target for the development of new drugs against rheumatoid arthritis. Using computational virtual screening techniques, families of pharmacologically active molecules have been identified that interfere with the TCR/collagen II-MHCII interaction. The compounds identified here open up new possibilities in the treatment of rheumatoid arthritis.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: June 12, 2018
    Assignees: CONSIGLIO NAZIONALE DELLE RICERCHE, UNIVERSITÀ CATTOLICA DEL SACRO CUORE
    Inventors: Maria Cristina De Rosa, Francesco Ria, Bruno Giardina, Gianfranco Ferraccioli, Davide Pirolli, Chiara Nicolo′
  • Patent number: 9987251
    Abstract: Indolinone derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indolinone derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 5, 2018
    Assignee: Oncternal Therapeutics, Inc.
    Inventor: Jean-Michel Vernier
  • Patent number: 9988379
    Abstract: The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: June 5, 2018
    Assignee: LG CHEM, LTD.
    Inventors: Sung Bae Lee, Seung Yup Paek, Sook Kyung Yoon, Seung Hyun Yoon, Jeung Soon Choi
  • Patent number: 9975872
    Abstract: Provided are processes for the preparation of enantiomerically enriched or enantiomerically pure 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable form thereof.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: May 22, 2018
    Assignee: Celgene Corporation
    Inventors: John F. Traverse, Chengmin Zhang, Gregg B. Feigelson, Benjamin M. Cohen, William W. Leong
  • Patent number: 9969887
    Abstract: The present disclosure relates to a novel merocyanine-based compound capable of labeling biomolecules by intercalating biomolecules, and to a dye, kit and contrast medium composition for labelling biomolecules comprising the same.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: May 15, 2018
    Assignee: SFC Co., Ltd.
    Inventors: Su-Jin Kim, Do-Min Lee, Jong-Tae Je